ImClone Systems Inc (formerly IMCL)

[biophud]

Re: Corky/jbog-Annual report

When I went through the annual report, I did not see any new info. However, one sentence caught my eye.

"To avoid sacrificing the long term potential of the company to meet near-term expectations for growth and profitability, we have concluded that added scale is necessary" p44

A couple of quick comments/questions.

What does "additional scale mean"? Imclone would appear to have enough cash, enough production capacity, and a good early stage pipeline. Are they referring to clinical development teams and/or marketing/sales force teams that only a big pharma would have?

The strategic review has been conducted, IMCL was taken off the block, and now Carl is on board. Does IMCL still seek "additional scale"?

Any comments?

Biophud